Quipazine

CAT: 0804-HY-W028142-01Size: 50 mgDry Ice: NoHazardous: No
CAT#:0804-HY-W028142-01Size:50 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Quipazine is a 5-HT agonist with a Ki value of 1.4 nM for displaces [3H]GR65630 from 5-HT3R in rat. Quipazine shows antiviral activity against SARS-CoV-2 with an EC50 of 31.64 μM. Quipazine behaves as a 5-HT3R agonist in peripheral models. Quipazine can be used for neurological disease research[1][2][3][4].
CAS Number
[4774-24-7]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
5-HT Receptor; SARS-CoV
Type
Reference compound
Related Pathways
Anti-infection; GPCR/G Protein; Neuronal Signaling
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/quipazine.html
Purity
97.0
Solubility
DMSO : 8.33 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
C1(N2CCNCC2)=NC3=CC=CC=C3C=C1
Molecular Formula
C13H15N3
Molecular Weight
213.28
Precautions
H302, H315, H319, H335
References & Citations
[1]Mok E, et al. Effect of quipazine, a selective 5-HT3 agonist, on dietary self-selection of different macronutrient diets in male and female rats. Appetite. 2000 Jun;34 (3) :313-25.|[2]Günther S, et al. X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease. Science. 2021 May 7;372 (6542) :642-646.|[3]Glennon RA, et al. 5-HT1 and 5-HT2 binding characteristics of some quipazine analogues. J Med Chem. 1986 Nov;29 (11) :2375-80.|[4]Ireland SJ, Tyers MB. Pharmacological characterization of 5-hydroxytryptamine-induced depolarization of the rat isolated vagus nerve. Br J Pharmacol. 1987 Jan;90 (1) :229-38.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Related Products

Popular Products